JP5971971B2 - Wound dressing comprising a film or sheet containing a mixture of a polypeptide having a high antibacterial activity and a polysaccharide that does not inhibit the antibacterial activity - Google Patents

Wound dressing comprising a film or sheet containing a mixture of a polypeptide having a high antibacterial activity and a polysaccharide that does not inhibit the antibacterial activity Download PDF

Info

Publication number
JP5971971B2
JP5971971B2 JP2012031409A JP2012031409A JP5971971B2 JP 5971971 B2 JP5971971 B2 JP 5971971B2 JP 2012031409 A JP2012031409 A JP 2012031409A JP 2012031409 A JP2012031409 A JP 2012031409A JP 5971971 B2 JP5971971 B2 JP 5971971B2
Authority
JP
Japan
Prior art keywords
polypeptide
antibacterial activity
film
seq
polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012031409A
Other languages
Japanese (ja)
Other versions
JP2013166726A (en
Inventor
大野 徹
徹 大野
龍平 岡町
龍平 岡町
英樹 冨岡
英樹 冨岡
奈緒 田村
奈緒 田村
昭子 天満
昭子 天満
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FUNPEP CO., LTD.
Morishita Jintan Co Ltd
Original Assignee
FUNPEP CO., LTD.
Morishita Jintan Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FUNPEP CO., LTD., Morishita Jintan Co Ltd filed Critical FUNPEP CO., LTD.
Priority to JP2012031409A priority Critical patent/JP5971971B2/en
Publication of JP2013166726A publication Critical patent/JP2013166726A/en
Application granted granted Critical
Publication of JP5971971B2 publication Critical patent/JP5971971B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Description

本発明は、抗菌活性の高いポリペプチドとその抗菌活性を阻害しない多糖類との混合物を含有するフィルムまたはシートからなる創傷被覆材に関する。   The present invention relates to a wound dressing comprising a film or sheet containing a mixture of a polypeptide having a high antibacterial activity and a polysaccharide that does not inhibit the antibacterial activity.

創傷治癒過程には多くの細胞や因子が関与し、それらの連携が行われている。皮膚には本来自己修復力があるが、受傷部位が広範囲におよび感染の危険が伴う場合や合併症などで治癒力が衰えている場合には皮膚代替物で創傷面を被覆して自己修復能力を最大限に発揮できる環境が提供される必要がある。実際に創傷面を被覆し、創傷治癒に適した環境を維持・促進し、感染を防ぐために創傷被覆材が臨床的に用いられている。   Many cells and factors are involved in the wound healing process, and their cooperation is performed. The skin is inherently self-healing, but if the area of injury is wide, and there is a risk of infection or if the healing power is reduced due to complications, the wound surface is covered with a skin substitute and self-healing ability It is necessary to provide an environment in which Wound dressings are used clinically to actually cover the wound surface, maintain and promote an environment suitable for wound healing, and prevent infection.

これまでに臨床的に用いられている創傷被覆材としては、凍結乾燥豚皮、アルギン酸塩ゲル、コラーゲン不織布、キチン不織布、ポリウレタン膜などが開発されている。体液を吸収し、親水性のゲルを形成し、水分環境を整えることで創傷治癒を促したり、生体の結合組織の主成分を用いることで生体適合性を上げることで創傷治癒を促したりするものがある。   As wound dressings that have been used clinically so far, freeze-dried pig skin, alginate gel, collagen non-woven fabric, chitin non-woven fabric, polyurethane film and the like have been developed. It absorbs bodily fluids, forms a hydrophilic gel, promotes wound healing by preparing a moisture environment, or promotes wound healing by increasing biocompatibility by using the main components of connective tissue of the living body There is.

また、水蒸気を通すものの液体の水は通さない、通気性を有するフィルムやシートも開発されており、先の創傷被覆材と組み合わせた新たな創傷被覆材の開発が行われている。   In addition, breathable films and sheets that allow water vapor to pass but not liquid water have been developed, and new wound dressings combined with the previous wound dressings are being developed.

実際に、上記の機能を持つ創傷被覆材として合成ポリペプチドおよび多糖類からなる「保湿フィルムまたはシート」(特許文献1)が開示されているが、より優れた機能を持つポリペプチドを用いた安定な創傷被覆材の開発が望まれていた。   Actually, a “moisturizing film or sheet” (Patent Document 1) composed of a synthetic polypeptide and a polysaccharide has been disclosed as a wound dressing material having the above functions. Development of a new wound dressing has been desired.

より詳述すると、特許文献1には「合成ポリペプチドとしては、α−ヘリックス形成能のあるものであればいずれのものを用いてもよい。α−ヘリックス形成能のある合成ポリペプチドとしてはポリ−γ−メチル−L−グルタメート、ポリ−γ−エチル−L−グルタメート、ポリ−γ−ベンジル−L−グルタメート等のポリ−γ−グルタミン酸誘導体、ポリ−β−ベンジル−L−アスパルテート等のポリ−L−アスパラギン酸誘導体、ポリ−L−アラニン、ポリ−L−ロイシン等があげられる。」との記載(段落0008)があるのみであり、本発明にかかる配列番号1ないし配列番号11からなるポリペプチドのような、多種類のアミノ酸から構成されるポリペプチドに関する記載や示唆は全くなく、本発明のようなより優れた薬理活性を有するポリペプチドを含有し安定な新たな創傷被覆材の開発が望まれていた。   More specifically, Patent Document 1 states that “As a synthetic polypeptide, any polypeptide having an α-helix-forming ability may be used. As a synthetic polypeptide having an α-helix-forming ability, Poly-γ-glutamic acid derivatives such as -γ-methyl-L-glutamate, poly-γ-ethyl-L-glutamate, poly-γ-benzyl-L-glutamate, poly-β-benzyl-L-aspartate, etc. -L-aspartic acid derivatives, poly-L-alanine, poly-L-leucine and the like "(paragraph 0008) only, and consists of SEQ ID NO: 1 to SEQ ID NO: 11 according to the present invention. There is no description or suggestion regarding a polypeptide composed of many kinds of amino acids, such as a polypeptide, and a polypeptide having superior pharmacological activity as in the present invention. It has been desired to develop a new wound dressing containing a peptide and stable.

さらに該公報には「本発明における多糖類としては、ペクチン酸、ヒアルロン酸、ヘパリン、コンドロイチン硫酸等のムコ多糖類またはその塩があげられる。このうち、ヒアルロン酸は、多くの生理機能に関与すると共に、分子構造に由来する優れた吸湿性を有し、巨大なランダムコイル構造を形成するため特に好ましい。」との記載(段落0013)があるのみであり、本発明にかかるプルランまたはデンプンに関する記載や示唆は全くなく、本発明のポリペプチドと多糖類とを混合しても安定な新たな創傷被覆材の開発が望まれていた。   Further, the publication discloses "mucopolysaccharides such as pectic acid, hyaluronic acid, heparin, chondroitin sulfate, and salts thereof as the polysaccharide in the present invention. Of these, hyaluronic acid is involved in many physiological functions. In addition, it has an excellent hygroscopic property derived from the molecular structure and is particularly preferable because it forms a huge random coil structure ”(paragraph 0013), and is a description of pullulan or starch according to the present invention. There is no suggestion, and there has been a demand for the development of a new wound dressing that is stable even when the polypeptide of the present invention and the polysaccharide are mixed.

特開平9−010294号公報JP-A-9-010294

従来の創傷被覆材では感染を防ぐ効果が十分でなく、より優れた創傷治癒に適した環境を維持し、治癒効果を発揮する創傷被覆材が求められている。   Conventional wound dressings are insufficient in preventing infection, and there is a need for wound dressings that maintain an environment suitable for better wound healing and exhibit healing effects.

本発明の目的は、より有効な創傷治癒促進作用を誘導するために抗菌活性に優れたポリペプチドを有効成分として含有し、その抗菌活性を阻害することなく安定化させる多糖類との混合物を開発し、その混合物を含有するフィルムまたはシートからなる創傷被覆材を提供することである。   The purpose of the present invention is to develop a mixture with a polysaccharide that contains a polypeptide having an excellent antibacterial activity as an active ingredient in order to induce a more effective wound healing promotion effect and stabilizes the antibacterial activity without inhibiting it. And providing a wound dressing comprising a film or sheet containing the mixture.

本発明の創傷被覆材は、配列番号1ないし配列番号11からなるポリペプチドを有効成分として含有する。前記のポリペプチドは公知化合物であり、例えばWO2010/061915公報記載の方法に従いペプチド合成機を用いるか、あるいは液相ブロック合成法等の常法により製造することができる。
さらに本発明は、これらの抗菌活性ポリペプチドを特定の多糖類と混合し、加工してもその抗菌活性を阻害することなく、安定なフィルムまたはシートからなる創傷被覆材を作成したことに特徴がある。
The wound dressing of the present invention contains the polypeptide consisting of SEQ ID NO: 1 to SEQ ID NO: 11 as an active ingredient. The aforementioned polypeptide is a known compound, and can be produced, for example, using a peptide synthesizer according to the method described in WO2010 / 061915 or by a conventional method such as a liquid phase block synthesis method.
Furthermore, the present invention is characterized in that a wound dressing comprising a stable film or sheet is prepared without inhibiting the antibacterial activity even if these antibacterial active polypeptides are mixed with a specific polysaccharide and processed. is there.

すなわち、本発明は、
(1) 配列番号1ないし配列番号11からなるポリペプチドもしくはそのアミノ酸配列に対し95%以上の相同性を有するポリペプチドから選ばれた1種以上のポリペプチドまたはその薬理学的に許容される塩、およびプルランまたはデンプンからなる、フィルムまたはシート。
(2) 配列番号1もしくはそのアミノ酸配列に対し95%以上の相同性を有するポリペプチドまたはその薬理学的に許容される塩、およびプルランまたはデンプンからなる、フィルムまたはシート。
(3) 配列番号1からなるポリペプチドまたはその薬理学的に許容される塩およびプルランまたはデンプンからなる、フィルムまたはシート。
(4) 配列番号1からなるポリペプチドまたはその薬理学的に許容される塩およびプルランからなる、フィルムまたはシート。
(5) 配列番号1からなるポリペプチドまたはその薬理学的に許容される塩およびデンプンからなる、フィルムまたはシート。
(6) (1)ないし(5)に記載のフィルムまたはシートからなる、創傷被覆材。
That is, the present invention
(1) one or more polypeptides selected from the polypeptide consisting of SEQ ID NO: 1 to SEQ ID NO: 11 or a polypeptide having homology of 95% or more to the amino acid sequence or a pharmacologically acceptable salt thereof And a film or sheet consisting of pullulan or starch.
(2) A film or sheet comprising SEQ ID NO: 1 or a polypeptide having 95% or more homology to its amino acid sequence or a pharmacologically acceptable salt thereof, and pullulan or starch.
(3) A film or sheet comprising a polypeptide consisting of SEQ ID NO: 1 or a pharmacologically acceptable salt thereof and pullulan or starch.
(4) A film or sheet comprising the polypeptide consisting of SEQ ID NO: 1 or a pharmacologically acceptable salt thereof and pullulan.
(5) A film or sheet comprising a polypeptide comprising SEQ ID NO: 1 or a pharmacologically acceptable salt thereof and starch.
(6) A wound dressing comprising the film or sheet according to (1) to (5).

本発明により、抗菌活性に優れたポリペプチドとその抗菌活性を阻害しない多糖類との混合物を含有するフィルムまたはシートからなる創傷被覆材が提供される。   The present invention provides a wound dressing comprising a film or sheet containing a mixture of a polypeptide excellent in antibacterial activity and a polysaccharide that does not inhibit the antibacterial activity.

本発明の「ポリペプチド」と「ペプチド」の語は同義に用いられる。   The terms “polypeptide” and “peptide” of the present invention are used interchangeably.

本発明の抗菌活性における評価において使用されるトブラマイシン(Tobramycin : TOB)は緑膿菌や変形菌に有効なアミノグリコシド系抗生物質で、抗菌活性を有する。トブラマイシンを陽性対象として、本願発明のポリペプチドと多糖類の混合物における抗菌活性を調べた。
その結果、上記の本発明のポリペプチドと特定の多糖類との混合物が、優れた抗菌活性を有することが下記の実施例1に示されるように明らかとなった。
Tobramycin (TOB) used in the evaluation of antibacterial activity of the present invention is an aminoglycoside antibiotic effective against Pseudomonas aeruginosa and deformed bacteria and has antibacterial activity. The antibacterial activity of the mixture of the polypeptide of the present invention and the polysaccharide was examined using tobramycin as a positive target.
As a result, it was clarified that the mixture of the polypeptide of the present invention and the specific polysaccharide has excellent antibacterial activity as shown in Example 1 below.

本発明のポリペプチドは、アミノ末端(N末端)及び/又はカルボキシル末端(C末端)が修飾されていても良い。N末端は修飾されず、C末端がアミド化されていることが好ましい。
本発明のポリペプチドは、キャッピング構造を付加しても良い。ここで、キャッピング構造は、ポリペプチドのN末端及び/又はC末端に、ポリペプチドの構造を安定化させることが知られている。
The polypeptide of the present invention may be modified at the amino terminus (N terminus) and / or the carboxyl terminus (C terminus). It is preferable that the N-terminus is not modified and the C-terminus is amidated.
A capping structure may be added to the polypeptide of the present invention. Here, the capping structure is known to stabilize the structure of the polypeptide at the N-terminus and / or C-terminus of the polypeptide.

本発明のポリペプチドは、市販のペプチド合成機を用いた化学合成等の常法により容易に製造することができる。また、安定化修飾も周知の方法により容易に行うことができる。   The polypeptide of the present invention can be easily produced by a conventional method such as chemical synthesis using a commercially available peptide synthesizer. In addition, stabilization modification can be easily performed by a known method.

プルラン(pullulan) はグルコースからなる多糖類の一種であり、日本薬局方に収載された医療用添加物である。また化粧品添加物や食品添加物としても利用されている。化学的にはグルコース3分子がα1-4結合したマルトトリオースがα1-6結合で繋がった構造を有する。
さらに物理化学的には高い水溶性を有し、増粘性、接着性、付着性、粘着性、造膜性、被膜性などに優れ、可食性である。このような性質から、一定量の水を加え加熱成型すると、生分解性/可食性のフィルムやカプセルなどを作ることができる。
Pullulan is a kind of polysaccharide consisting of glucose, and is a medical additive listed in the Japanese Pharmacopoeia. It is also used as a cosmetic additive and food additive. Chemically, it has a structure in which maltotriose, in which three glucose molecules are α1-4 linked, is linked by α1-6 bonds.
Furthermore, in terms of physicochemical properties, it has high water solubility, is excellent in viscosity increase, adhesiveness, adhesion, tackiness, film-forming property, film-forming property, etc. Because of these properties, biodegradable / edible films and capsules can be made by heating and molding a certain amount of water.

ペクチンはガラクツロン酸、ラムノース、他30種類の多糖である。ホモガラクツロナン(HG)、ラムノガラクツロナン−I(RG−I)、ラムノガラクツロナン−II(RG−II)の3つのユニットから形成されている。   Pectin is galacturonic acid, rhamnose, and 30 other polysaccharides. It is formed from three units of homogalacturonan (HG), rhamnogalacturonan-I (RG-I), and rhamnogalacturonan-II (RG-II).

デンプンはグルコースからなる多糖である。直鎖状のアミロース、分岐のあるアミロペクチンからなる。   Starch is a polysaccharide consisting of glucose. It consists of linear amylose and branched amylopectin.

本発明のポリペプチドは、特定の多糖類と混合して安定化され、フィルム状またはシート状の創傷被覆材として用いる。   The polypeptide of the present invention is stabilized by mixing with a specific polysaccharide and used as a wound dressing in the form of a film or a sheet.

本発明のポリペプチドを含有するフィルムまたはシートからなる創傷被覆材は、ガーゼ、包帯、綿、織布、不織布、編物、ニット布、圧着シート、圧定布、ウレタンフォームまたは紙などの基材と組み合わせて使用することもできる。   A wound dressing comprising a film or sheet containing the polypeptide of the present invention comprises a base material such as gauze, bandage, cotton, woven fabric, non-woven fabric, knitted fabric, knitted fabric, pressure-bonding sheet, compression fabric, urethane foam or paper. It can also be used in combination.

本発明のポリペプチドを含有する創傷被覆材に含有されるポリペプチドの量は限定されないが、通常は創傷被覆材中に0.001〜5重量%、好ましくは0.01〜2重量%、さらに好ましくは0.1〜1重量%の範囲である。   The amount of the polypeptide contained in the wound dressing containing the polypeptide of the present invention is not limited, but is usually 0.001 to 5% by weight in the wound dressing, preferably 0.01 to 2% by weight, more preferably 0.1 to It is in the range of 1% by weight.

以下、本発明を実施例に基づきより具体的に説明する。ただし、本発明は下記実施例に限定されるものではない。   Hereinafter, the present invention will be described more specifically based on examples. However, the present invention is not limited to the following examples.

用いた抗菌活性ポリペプチドを以下に示す。   The antimicrobially active polypeptides used are shown below.

SR−1(配列番号1) GRLKRMGERLKRKIQKWIRW− Amide
SR−2(配列番号2) IFLHRLKRMRKRLKRKLRLW
SR−3(配列番号3) RLKRMRKRLKRKLRLWHRKRYK− Amide
SR−4(配列番号4) MLKLIFLHRLKRMRKRLKRKLR− Amide
SR−5(配列番号5) MLKLIFLHRLKRMRKRLKRK− Amide
SR−6(配列番号6) LKLIFLHRLKRMRKRLKRKL− Amide
SR−7(配列番号7) LIFLHRLKRMRKRLKRKLRL− Amide
SR−8(配列番号8) KLIFLHRLKRELRKRLKRKLR− Amide
SR−9(配列番号9) GRLKRMGKRLKRKIQKWARW− Amide
SR−10(配列番号10) KLIFLRELRRLRKRLKRKLR− Amide
SR−11(配列番号11) RLKRMRKRLKRKLRLW− Amide
SR-1 (SEQ ID NO: 1) GRLKRMGERLKRKIQKWIRW- Amide
SR-2 (SEQ ID NO: 2) IFLHRLKRMRKRLKRKLRLW
SR-3 (SEQ ID NO: 3) RLKRMRKRLKRKLRLWHRKRYK- Amide
SR-4 (SEQ ID NO: 4) MLKLIFLHRLKRMRKRLKRKLR- Amide
SR-5 (SEQ ID NO: 5) MLKLIFLHRLKRMRKRLKRK- Amide
SR-6 (SEQ ID NO: 6) LKLIFLHRLKRMRKRLKRKL- Amide
SR-7 (SEQ ID NO: 7) LIFLHRLKRMRKRLKRKLRL- Amide
SR-8 (SEQ ID NO: 8) KLIFLHRLKRELRKRLKRKLR- Amide
SR-9 (SEQ ID NO: 9) GRLKRMGKRLKRKIQKWARW- Amide
SR-10 (SEQ ID NO: 10) KLIFLRELRRLRKRLKRKLR- Amide
SR-11 (SEQ ID NO: 11) RLKRMRKRLKRKLRLW- Amide

1.多糖類の混合によるポリペプチドの抗菌活性への影響
ペクチンおよびその他各種の多糖類によるポリペプチドの抗菌活性への影響を検討した。本明細書において陽性対照であるトブラマイシンはTOBと呼ぶ。
(方法)
菌株には、グラム陽性菌として黄色ブドウ球菌(Staphylococcus aureus)およびグラム陰性菌として緑膿菌(Pseudomonas aeruginosa)、大腸菌(Escherichia coli)を用いた。1%アガロース入りミューラー・ヒントン・ブロス(Mueller-Hinton broth:MHB)培地に1%多糖類となるように混合し、培地をオートクレーブ滅菌した。
TOBおよび配列番号1で表されるポリペプチドを最終濃度の10倍に調整し、シャーレに1mL添加して、培地9mLと十分に混合して混釈培地を作製した(n=3)。
各菌株の菌数を最終濃度で10,000CFU/plate程度になるように塗布し、一晩培養した。
培養後、コロニーの生育を観察した。ポリペプチド未添加のものを陰性対照とし、TOB添加のものを陽性対照とした。さらに多糖類はプルラン、ペクチン、CMC、ローカストビーンガム、タラガム、デンプン、アガーを用いた。
結果の判定には、コロニーが生育した培地を『+』、生育を阻止した培地を『−』と表記し、2回の試験(n=3を2回)で生育と生育阻止と判定が分かれた培地は『±』と表記した。
1. Effect of Polysaccharide Mixture on Antibacterial Activity of Polypeptide The effect of pectin and other polysaccharides on the antibacterial activity of polypeptide was investigated. Tobramycin, which is a positive control herein, is referred to as TOB.
(Method)
As strains, Staphylococcus aureus was used as a gram-positive bacterium, Pseudomonas aeruginosa and Escherichia coli were used as gram-negative bacteria. A 1% agarose-containing Mueller-Hinton broth (MHB) medium was mixed with 1% polysaccharide, and the medium was autoclaved.
TOB and the polypeptide represented by SEQ ID NO: 1 were adjusted to 10 times the final concentration, 1 mL was added to the petri dish, and mixed well with 9 mL of medium to prepare a pour medium (n = 3).
Each bacterial strain was applied at a final concentration of about 10,000 CFU / plate and cultured overnight.
After culturing, the growth of colonies was observed. A non-polypeptide added was used as a negative control, and a TOB added was used as a positive control. Further, pullulan, pectin, CMC, locust bean gum, tara gum, starch, and agar were used as polysaccharides.
For the determination of the result, the culture medium on which the colony grew was indicated as “+”, the culture medium that inhibited the growth was indicated as “−”, and the determination of growth and growth inhibition was separated in two tests (n = 3 twice). The medium was indicated as “±”.

結果を表1に示す。

Figure 0005971971
The results are shown in Table 1.
Figure 0005971971

(結果)
プルランとデンプンは、3種の菌株において配列番号1で表されるポリペプチドの抗菌活性を阻害しなかった。プルランとデンプンの構成糖はグルコースのみであることから、グルコースは前記のポリペプチドの抗菌活性を阻害しないと考えられた。
グアーガムは、粘性が高く検討できなかった。しかし糖構成が同じローカストビーンガムやタラガムにより前記のポリペプチドの抗菌活性が阻害されていることから、グアーガムも同様に抗菌活性を阻害するものと考えられた。
(result)
Pullulan and starch did not inhibit the antimicrobial activity of the polypeptide represented by SEQ ID NO: 1 in the three strains. Since the constituent sugars of pullulan and starch are only glucose, it was considered that glucose does not inhibit the antibacterial activity of the polypeptide.
Guar gum was too viscous to be examined. However, since the antibacterial activity of the above-mentioned polypeptide is inhibited by locust bean gum or tara gum having the same sugar composition, it was considered that guar gum similarly inhibits the antibacterial activity.

前記の特開平9−010294号公報には、使用可能な具体例としてペクチン酸が例示されているが、それに反し上記の結果から明らかなように、配列番号1で表されるポリペプチドに対してペクチンは安定性を損ね、プルランまたはデンプンのみが安定性を有することは驚くべき効果である。
なお化学的には、構成単位であるガラクツロン酸のカルボキシル基がメチルエステル化されたものをペクチン、メチルエステル化されていないものをペクチン酸と呼ぶが、天然物ではガラクツロン酸の一部がメチル化され、一部はカルボキシル基フリーで混在していることが多い。
In the above-mentioned JP-A-9-010294, pectinic acid is exemplified as a usable example. On the other hand, as apparent from the above results, the polypeptide represented by SEQ ID NO: 1 is described. Pectin loses stability and it is a surprising effect that only pullulan or starch has stability.
Chemically, galacturonic acid which is a structural unit is called pectin when its carboxyl group is methylesterified, and pectinic acid when it is not methylesterified. In natural products, part of galacturonic acid is methylated. Some of them are often free of carboxyl groups.

Claims (5)

配列番号1もしくはそのアミノ酸配列に対し95%以上の相同性を有するポリペプチドまたはその薬理学的に許容される塩、およびプルランまたはデンプンからなる、フィルムまたはシート。   A film or sheet comprising SEQ ID NO: 1 or a polypeptide having a homology of 95% or more to its amino acid sequence or a pharmacologically acceptable salt thereof, and pullulan or starch. 配列番号1からなるポリペプチドまたはその薬理学的に許容される塩およびプルランまたはデンプンからなる、フィルムまたはシート。   A film or sheet comprising a polypeptide consisting of SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof and pullulan or starch. 配列番号1からなるポリペプチドまたはその薬理学的に許容される塩およびプルランからなる、フィルムまたはシート。   A film or sheet comprising the polypeptide consisting of SEQ ID NO: 1 or a pharmacologically acceptable salt thereof and pullulan. 配列番号1からなるポリペプチドまたはその薬理学的に許容される塩およびデンプンからなる、フィルムまたはシート。   A film or sheet comprising a polypeptide comprising SEQ ID NO: 1 or a pharmacologically acceptable salt thereof and starch. 請求項1ないしのいずれか1項に記載のフィルムまたはシートからなる、創傷被覆材。 A wound dressing comprising the film or sheet according to any one of claims 1 to 4 .
JP2012031409A 2012-02-16 2012-02-16 Wound dressing comprising a film or sheet containing a mixture of a polypeptide having a high antibacterial activity and a polysaccharide that does not inhibit the antibacterial activity Active JP5971971B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012031409A JP5971971B2 (en) 2012-02-16 2012-02-16 Wound dressing comprising a film or sheet containing a mixture of a polypeptide having a high antibacterial activity and a polysaccharide that does not inhibit the antibacterial activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012031409A JP5971971B2 (en) 2012-02-16 2012-02-16 Wound dressing comprising a film or sheet containing a mixture of a polypeptide having a high antibacterial activity and a polysaccharide that does not inhibit the antibacterial activity

Publications (2)

Publication Number Publication Date
JP2013166726A JP2013166726A (en) 2013-08-29
JP5971971B2 true JP5971971B2 (en) 2016-08-17

Family

ID=49177449

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012031409A Active JP5971971B2 (en) 2012-02-16 2012-02-16 Wound dressing comprising a film or sheet containing a mixture of a polypeptide having a high antibacterial activity and a polysaccharide that does not inhibit the antibacterial activity

Country Status (1)

Country Link
JP (1) JP5971971B2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63109865A (en) * 1986-06-23 1988-05-14 東洋製薬化成株式会社 Pullulan film preparation containing drug as effective component
FR2933959B1 (en) * 2008-07-16 2010-09-10 Roquette Freres PROCESS FOR PRODUCING FILMS DIRECTLY IN ALVEOL
WO2010101237A1 (en) * 2009-03-06 2010-09-10 アンジェスMg株式会社 Polypeptides and antibacterial or antiseptic use of same

Also Published As

Publication number Publication date
JP2013166726A (en) 2013-08-29

Similar Documents

Publication Publication Date Title
KR102667393B1 (en) Wound dressing comprising hyaluronic acid-calcium and polylysine, and preparation method thereof
Zamboni et al. Hyaluronic acid association with bacterial, fungal and viral infections: Can hyaluronic acid be used as an antimicrobial polymer for biomedical and pharmaceutical applications?
AU2019265757B2 (en) Wound dressing for treatment of damaged skin
Tang et al. Application of chitosan and its derivatives in medical materials
Shanmugasundaram et al. Fabrication and characterization of chicken feather keratin/polysaccharides blended polymer coated nonwoven dressing materials for wound healing applications
JP2011522879A5 (en)
EP3060266B1 (en) Chitosan paste wound dressing
JP2009505687A (en) Biomaterial based on zinc chlorided carboxymethylcellulose in combination with hyaluronic acid derivatives for use as a medical device having antibacterial and antifungal activity, and method for producing the same
KR101820306B1 (en) Gallic Acid-Chitosan Complexes and Composition for Wound Healing Comprising Them
CN102335451A (en) Medical colloid dressing with functions for inhibiting bacteria and promoting heal and application thereof
CN102335452A (en) Formula of functional dressing and preparation method thereof
Khan et al. Development of hydrocolloid Bi-layer dressing with bio-adhesive and non-adhesive properties
Kumar et al. Recent advances in the use of algal polysaccharides for skin wound healing
CN106215239B (en) A kind of preparation method of crosslinked antimicrobial type acellular matrix material
WO2017101020A1 (en) Modified dressing
CN104740141B (en) A kind of antimicrobial spray and preparation method thereof
CN103816560A (en) Colloidal fluid used for wound restoration and preparation method thereof
Balakrishnan et al. Anti-bacterial Properties of an in situ Forming Hydrogel Based on Oxidized Alginate and Gelatin Loaded with Gentamycin.
CN115869459A (en) Polypeptide hydrogel for promoting wound healing and preparation method and application thereof
Xie et al. A multifunctional and self-adaptive double-layer hydrogel dressing based on chitosan for deep wound repair
Watson et al. Hyaluronic acid-based antibacterial hydrogels for use as wound dressings
JP5971971B2 (en) Wound dressing comprising a film or sheet containing a mixture of a polypeptide having a high antibacterial activity and a polysaccharide that does not inhibit the antibacterial activity
CN112891615A (en) Liquid adhesive bandage and preparation method thereof
RU2582220C1 (en) Wound dressing based on chitosan
CN104147632A (en) Chitosan wound-caring liquid dressing characterized by specific cell adhesion

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150115

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160510

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160712

R150 Certificate of patent or registration of utility model

Ref document number: 5971971

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250